Single center study of efficacy and safety of capivasertib in hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC)

A retrospective analysis reviewed data from 34 patients with HR+ HER2- metastatic breast cancer who were treated with capivasertib at Moffitt Cancer Center after its 2023 approval. The results suggest that capivasertib may represent a viable treatment option for patients who were previously treated with alpelisib.